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Vortioxetine is a multimodal antidepressant that binds with high 
affinity the serotonin transporter (SERT) > (serotonin receptor) 
5-HT3 > 5-HT1A > 5-HT7 > 5-HT1B > 5-HT1D. It acts by inhibiting 
the SERT, with antagonism activity on the 5-HT1D, 5-HT7 and 
5-HT3 receptors, partial agonism activity on the 5-HT1B receptor, 
agonism activity at 5HT1A receptor1. Vortioxetine is a compound 
approved by the FDA for major depressive disorder. Its efficacy 
and tolerability are widely proven2. Regarding tolerability, both 
in short and long-term studies, nausea was the most common 
treatment emergent adverse event (TEAE) and the primary TEAE 
that caused discontinuation after vortioxetine treatment2-4. Nausea 
is one of the most frequently reported adverse effects after SSRI and 
SNRI treatment. This can be attributed to their action on serotonin 
levels and on receptor 5-HT35. Nausea management includes: 
splitting daily dosage, taking medication after a meal, using drugs 
like 5-HT2 antagonists, proton pump inhibitors, promethazine, 
prochlorperazine, or ondansetron6. It is well established how the 
antidepressant tolerability influences quality of life and adherence 
to pharmacological treatment7. In this study we describe a case of 
nausea induced by vortioxetine along with its following treatment 
in a 32-year-old Italian patient with a diagnosis of bipolar disorder 
type 2, most recent depressive episode. At the time of our evaluation 
the patient was treated with lurasidone 37 mg/day and lithium 
carbonate 600 mg/day. In the past, trials with SSRIs and SNRIs 
have been conducted with improvement of depressive symptoms 
but the onset of sexual dysfunction led to drug discontinuation. 
A trial with bupropion was reported to have induced the onset of 
anxious symptoms. A trial was then started with vortioxetine 10 
mg, increased to 20 mg after 8 days, then nausea occurred. It was 
decided to introduce mirtazapine 15 mg in the evening. After 2 days 
of mirtazapine augmentation the patient reported improvement in 
the nausea that was maintained at follow up; in addition, 2 weeks 
later an improvement in mood, anxiety, sleep regularity was observed, 
as well as the absence of sexual dysfunctions. In our case report 
we used mirtazapine in augmentation to vortioxetine following a 
pharmacodynamic and clinical reasoning. Mirtazapine, thanks to its 
5-HT3 antagonism, has antiemetic properties already recognized in 
the literature8. Although the same 5-HT3 antagonism is universally 
accepted for vortioxetine as well, a recent study has shown a different 
behavior of vortioxetine on 5-HT3 receptors than that hypothesized 
so far: it can have, in fact, a significative agonist activity. Quoting: 
“[…] the mechanism of vortioxetine differs from classical 5-HT3A 
orthosteric ligands with inhibitory activity […] vortioxetine binding 
induces a brief agonistic response followed by a rapid transition 
into a desensitized state from which vortioxetine has an extremely 
slow unbinding rate”9. Our case report suggests the possible role of 
mirtazapine against antidepressant-induced nausea. Further studies 
are needed to investigate how these data could be useful to explain 
and manipulate the clinical effects in terms of efficacy and tolerability. 
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